文献速递乳腺癌放疗姑息放疗与转移瘤

霍奇金淋巴瘤女性不同放疗体积下的继发性乳腺癌风险

Secondary Breast Cancer Risk by Radiation Volume in Women With Hodgkin Lymphoma.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2016-10-13

该研究基于BC Cancer Agency淋巴瘤数据库,纳入1961年至2009年间治疗的734例女性霍奇金淋巴瘤患者,比较斗篷野放疗(MRT)、小野放疗(SFRT)和单纯化疗后继发性乳腺癌(SBC)的风险。20年累积发生率MRT为7.5%、SFRT为3.1%、单纯化疗为2.2%(P=.01);多因素分析显示MRT较单纯化疗(HR=2.9)和SFRT(HR=3.3)显著增加SBC风险,而SFRT与单纯化疗无显著差异。

要点

  • 斗篷野放疗20年继发性乳腺癌累积发生率为7.5%,显著高于小野放疗的3.1%和单纯化疗的2.2%。
  • 斗篷野放疗较单纯化疗(HR=2.9)和小野放疗(HR=3.3)均显著增加继发性乳腺癌风险。
  • 现代小体积放疗与单纯化疗相比未显著增加继发性乳腺癌风险(HR=0.87)。

核心结论

  • 大体积斗篷野放疗与继发性乳腺癌风险显著增加相关,而现代小体积放疗较单纯化疗未显著增加该风险。

研究设计与样本

  • 放疗体积分为斗篷野放疗(MRT)和小野放疗(SFRT,包括累及野、累及部位或累及淋巴结放疗),采用竞争风险分析和Fine-Gray多因素模型比较继发性乳腺癌风险。

主要发现

  • 734例 eligible 患者中,75%的存活患者随访超过10年,54例发生继发性乳腺癌,15例死于乳腺癌。
  • 20年竞争风险累积发生率:MRT 7.5%(95%CI 4.4%-11.5%),SFRT 3.1%(95%CI 1.0%-7.7%),单纯化疗2.2%(95%CI 1.0%-4.8%)(P=.01)。
  • Fine-Gray模型显示,MRT较单纯化疗(HR=2.9;95%CI 1.4%-6.0%;P=.004)和SFRT(HR=3.3;95%CI 1.3%-8.4%;P=.01)均与更高的继发性乳腺癌风险相关。
  • SFRT与单纯化疗相比,继发性乳腺癌风险无显著差异(HR=0.87;95%CI 0.28%-2.66%;P=.80)。

临床怎么用

  • 对于接受放疗的女性霍奇金淋巴瘤患者,采用现代小体积放疗技术可能降低继发性乳腺癌风险,应避免大体积斗篷野放疗。
  • 在制定放疗计划时,应优先考虑累及野、累及部位或累及淋巴结放疗等小体积照射方式。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine whether the risk of secondary breast cancer (SBC) is reduced in women with Hodgkin lymphoma (HL) treated with smaller field radiation therapy (SFRT) versus mantle field radiation therapy (MRT). METHODS AND MATERIALS: We used the BC Cancer Agency (BCCA) Lymphoid Cancer Database to identify female patients treated for HL between January 1961 and December 2009. Radiation therapy volumes were categorized as MRT or SFRT, which included involved field, involved site, or involved nodal radiation therapy. SBC risk estimates were compared using competing risk analysis and Fine and Gray multivariable model: MRT ± chemotherapy, SFRT ± chemotherapy, or chemotherapy-only. RESULTS: Of 734 eligible patients, 75% of the living patients have been followed up for more than 10 years, SBC has developed in 54, and 15 have died of breast cancer. The 20-year estimated risks (competing risk cumulative incidence) for SBC differed significantly: MRT 7.5% (95% confidence interval [CI] 4.4%-11.5%), SFRT 3.1% (95% CI 1.0%-7.7%), and chemotherapy-only 2.2% (95% CI 1.0%-4.8%) (P=.01). Using a Fine and Gray model to control for death and patients lost to follow-up, MRT was associated with a higher risk of SBC (hazard ratio [HR] = 2.9; 95% CI 1.4%-6.0%; P=.004) compared with chemotherapy-only and with SFRT (HR = 3.3; 95% CI 1.3%-8.4%; P=.01). SFRT was not associated with a greater risk of SBC compared with chemotherapy-only (HR = 0.87; 95% CI 0.28%-2.66%; P=.80). CONCLUSION: This study confirms that large-volume MRT is associated with a markedly increased risk of SBC; however, more modern small-volume RT is not associated with a greater risk of SBC than chemotherapy alone.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Conway JL, Connors JM, Tyldesley S, et al. Secondary Breast Cancer Risk by Radiation Volume in Women With Hodgkin Lymphoma. Int J Radiat Oncol Biol Phys. 2016. PMID: 27979454. doi:10.1016/j.ijrobp.2016.10.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。